CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that its lead asset THIO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results